Search results

Skip to results

Type

Status

Last updated

Showing 46 to 60 of 105 results for melanoma

  1. NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.

    vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. Any explanatory notes(if applicable) This may...

    Research recommendation
    Published
    9 June 2015

  2. Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This should be investigated in a placebo controlled randomised trial. Secondary outcomes should include disease specific survival and toxicity, including the development of renal stones and hypercalcaemia.

    Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This...

    Research recommendation
    Published
    4 August 2022

  3. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA442

  4. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 and over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. It aims to reduce variation in practice and improve survival.

    NICE guideline
    Last updated
    6 June 2018
    View recommendations

    Sections for NG36

  5. What proportion of people with melanoma who are referred into secondary care under the 2 week wait rule, have equivocal moles that are excised and have equivocal moles that are monitored?

    Recommendation ID DG19/2 Question What proportion of people with melanoma who are referred into secondary care under the 2 week wait...

    Research recommendation
    Published
    12 January 2016

  6. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

    Technology appraisal guidance
    Published
    28 May 2025

    Sections for TA1065

  7. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  8. What is the impact of using the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England, particularly on excision rates, diagnostic accuracy, health related quality of life and associated NHS costs?

    the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care...

    Research recommendation
    Published
    12 January 2016

  9. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    analysis of melanoma tissue samples. Full details of the evidence and the committee's discussion are in evidence review A: genetic...

    Research recommendation
    Published
    4 August 2022

  10. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [TSID12277]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  12. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  14. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTE24)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin...

    Health technology evaluation
    Published
    1 May 2025
    View recommendations

    Sections for HTE24

  15. Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

    Awaiting development Reference number: GID-TA11882 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development